Skip to main navigation Skip to search Skip to main content

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses

  • David Cameron
  • , Michelle Casey
  • , Michael Press
  • , Deborah Lindquist
  • , Tadeusz Pienkowski
  • , C. Gilles Romieu
  • , Stephen Chan
  • , Agnieszka Jagiello-Gruszfeld
  • , Bella Kaufman
  • , John Crown
  • , Arlene Chan
  • , Mario Campone
  • , Patrice Viens
  • , Neville Davidson
  • , Vera Gorbounova
  • , Johannes Isaac Raats
  • , Dimosthenis Skarlos
  • , Beth Newstat
  • , Debasish Roychowdhury
  • , Paolo Paoletti
    • Cristina Oliva, Stephen Rubin, Steven Stein, Charles E. Geyer
  • University of Leeds
  • NCRN Co-ordinating Center
  • GlaxoSmithKline
  • University of Southern California
  • US Oncology, Inc.
  • Maria Sklodowska-Curie Institute of Oncology
  • Centre régional de lutte du cancer Val d'Aurelle
  • Nottingham University Hospitals NHS Trust
  • ZOZ MSWiA
  • Sheba Medical Center at Tel Hashomer
  • Irish Clinical Oncology Research Group
  • Mount Hospital
  • Georges François Leclerc Cancer Center
  • Paoli-Institut Calmettes
  • Mid and South Essex NHS Foundation Trust
  • Russian National Cancer Research Center
  • Panorama Medi-Clinic
  • Errikos Dynan Hospital-B
  • West Penn Allegheny Health System

Research output: Contribution to journal › Article › peer-review

729 Scopus citations

Fingerprint

Dive into the research topics of 'A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Nursing and Health Professions